Milsom I, Altman D, Cartright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI) In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence - 6th International Consultation on Incontinence, ICS-ICUD, 2017:15-142.
Hunter KF, Wagg A, Kerridge T, Chick H, Chambers T. Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: a scoping review. Neurourol Urodyn 2011;30:490-4.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49.
Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. J Urol;188:2455-2463
Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. Eur Urol 2016;69:311-23.
Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov 2014;9:433-48.
Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence - 6th International Consultation on Incontinence, ICS-ICUD, 2017. pp. 805-957.
Coelho A, Antunes-Lopes T, Gillespie J, et al. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study. Neurourol Urodyn 2017;36:1972-1980.
Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (Blossom) shows novel 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2008;7:239.
Chapple C, Wyndaele JJ, Van Kerrebroeck P, et al. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol 2010;9:249
Milsom I, Altman D, Cartright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI) In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence - 6th International Consultation on Incontinence, ICS-ICUD, 2017:15-142.
Hunter KF, Wagg A, Kerridge T, Chick H, Chambers T. Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: a scoping review. Neurourol Urodyn 2011;30:490-4.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49.
Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. J Urol;188:2455-2463
Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. Eur Urol 2016;69:311-23.
Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov 2014;9:433-48.
Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence - 6th International Consultation on Incontinence, ICS-ICUD, 2017. pp. 805-957.
Coelho A, Antunes-Lopes T, Gillespie J, et al. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study. Neurourol Urodyn 2017;36:1972-1980.
Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (Blossom) shows novel 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2008;7:239.
Chapple C, Wyndaele JJ, Van Kerrebroeck P, et al. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol 2010;9:249
Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95.
Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283.295.
Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo controlled, multicentre study to assess the efficacy and safety of the beta3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313.320.
Otsuki H, Kosaka T, Nakamura K, et al. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45:53-60.
Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol 2017;9:137-154.
Wada N, Iuchi H, Kita M, et al. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder. Low Urin Tract Symptoms 2016;8:171-6.
Morin F, Blais AS, Nadeau G, et al. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol 2017;197:1158-1163.
Drake MJ, Nitti VW, Ginsberg DA, et al. Comparative assessment of the efficacy of onabotulinumtoxin A and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int 2017;120:611-622.
Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther 2017;11:463-467.
Chapple C, Kaplan S, Mitcheson D, et al. Randomised, double-blind, active-controlled phase III study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296.305.
Yoshida M, Nozawa Y, Kato D, et al. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder Aged. 75 Years: Analysis of a Japanese Post-Marketing Study. Low Urin Tract Symptoms 2017. doi: 10.1111/luts.12190. (Epub ahead of print)
Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40.
Chapple CR, Nazir J, Hakimi Z, et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol 2017;72:389-399.
Kato D, Uno S, Van Schyndle J, et al. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. Int J Urol 2017;24:757-764.
Burkhard FC, Bosch JLHR, Cruz F, et al. European Association of Urology Guidelines on Urinary Incontinence 2017. Accessed on October 16, 2017 from https://uroweb.org/guideline/urinary-incontinence/
Mirabegron for treating symptoms of overactive bladder. National Institute for Health and Care Excellence, 2013. Accessed on October 16, 2017 from https://www.nice.org.uk/guidance/ta290
Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 2015;67:577.588
Macdiarmid S, Al-Shukri S, Barkin J, et al. Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacinmonotherapy. J Urol 2016;196:809.818.
Gibson W, MacDiarmid S, Huang M, et al. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus 2017 Sep 12. pii: S2405-4569(17)30200-6. doi: 10.1016/j.euf.2017.08.008. (Epub ahead of print)
Shin JH, Kim A, Choo MS. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy. Investig Clin Urol 2017;58:261-266.
Groen-Wijnberg M, van Dijk J, Krauwinkel W, et al. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Eur J Drug Metab Pharmacokinet 2017;42:417-429.
